Macrophages in multiple myeloma

Immunology Letters

Volumn 161, Issue 2, 2014, Pages 241-244

  Ribatti, Domenico ^a,b   Moschetta, Michele ^a   Vacca, Angelo ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

Angiogenesis; Anti angiogenesis; Inflammation; Macrophages; Multiple myeloma

Indexed keywords

BORTEZOMIB; CD68 ANTIGEN; DEFIBROTIDE; ERYTHROPOIETIN; FIBROBLAST GROWTH FACTOR 2; PLATELET DERIVED GROWTH FACTOR; SCATTER FACTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VON WILLEBRAND FACTOR; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT;

ANTIANGIOGENIC THERAPY; ARTICLE; DRUG POTENTIATION; ENDOTHELIAL PROGENITOR CELL; HEMATOPOIETIC STEM CELL; HUMAN; MACROPHAGE ACTIVATION; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR VASCULARIZATION; ANIMAL; DRUG EFFECTS; IMMUNOLOGY; MACROPHAGE; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; ERYTHROPOIETIN; HUMANS; MACROPHAGES; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84906791594     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2013.12.010     Document Type: Article

References (36)

1. Virchow R. Die Krankenaften Geschwulste 1863, 1-255. August Hirschwald, Berlin.
2. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002, 23:549-555.
3. Aharinejad S., Sioud M., Lucas T., Abraham D. Target validation using RNA interference in solid tumors. Methods Mol Biol 2007, 361:227-238.
4. Lin E.Y., Nguyen A.V., Russell R.G., Pollard J.W. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001, 193:727-740.
5. Guruvayoorappan C. Tumor versus tumor-associated macrophages: how hot is the link?. Integr Cancer Ther 2008, 7:90-95.
6. Talmadge J.E., Donkor M., Scholar E. Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev 2007, 26:373-400.
7. Mantovani A., Locati M. Tumor-associated macrophages as a paradigm of macrophage plasticity, diversity and polarization. Lesson and open questions. Arterioscler Thromb Vasc Biol 2013, 33:1478-1483.
8. Gordon S., Martinez F.O. Alternative activation of macrophages: mechanism and functions. Immunity 2010, 32:593-604.
9. Sica A., Schioppa T., Mantovani A., Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 2006, 42:717-727.
10. Qian B.Z., Pollard J.M. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141:39-51.
11. Ribatti D., Crivellato E. Immune cells and angiogenesis. J Cell Mol Med 2009, 13:2822-2833.
12. Talks K.L., Tyrley H., Gatter K.C., Maxwell P.H., Pugh C.W., Ratcliffe P.J., et al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000, 157:411-421.
13. Ribatti D. Macrophages and tumor angiogenesis. Leukemia 2007, 21:2085-2089.
14. Vacca A., Ribatti D. Bone marrow angiogenesis in multiple myeloma. Leukemia 2006, 20:193-199.
15. Ribatti D., Nico B., Vacca A. Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma. Oncogene 2006, 25:4257-4266.
16. Ribatti D., Vacca A. The role of monocytes-macrophages in vasculogenesis in multiple myeloma. Leukemia 2009, 23:1535-1536.
17. Vacca A., Ribatti D., Presta M., Minischetti M., Iurlaro M., Ria R., et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999, 93:3064-3073.
18. Zheng Y., Cai Z., Wang S., Zhang X., Quian J., Hong S., et al. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood 2009, 114:3625-3628.
19. Chen H., Campbell R.A., Chang Y., Li M., Wang C.S., Li J., et al. Pleiotrophin produced by multiple myeloma induces transdifferentiation of monocytes into vascular endothelial cells: a novel mechanism of tumor-induced vasculogenesis. Blood 2008, 113:1992-2002.
20. Scavelli C., Nico B., Cirulli T., Ria R., Di Pietro G., Mangieri D., et al. Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma. Oncogene 2008, 27:663-674.
21. Kim J., Denu R.A., Dollar B.A., Escalante L.E., Kuether J.P., Callander N.S., et al. Macrophages and mesenchymal stromal cells supported survival and proliferation of multiple myeloma cells. Br J Haematol 2012, 158:336-346.
22. Gu Z.J., Costes V., Lu Z.Y., Zhang X.G., Pitara V., Moareau J.F., et al. Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop. Blood 1996, 88:3972-3986.
23. Li S., Zhang X., Xia X. Regression of tumor growth and induction of long-term antitumor memory by interleukin 12 electro-gene therapy. J Nat Cancer Inst 2002, 94:762-768.
24. Kim J., Hematti P. Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Exp Hematol 2009, 37:1445-1453.
25. Vilcek J. From IFN to TNF: a journey into realms of lore. Nat Immunol 2009, 10:555-557.
26. Airoldi I., Cocco C., Giuliani N., Ferrarini M., Colla S., Ognio E., et al. Constitutive expression of IL-12Rβ-2 on human multiple myeloma cells delineates a novel therapeutic target. Blood 2008, 112:750-759.
27. Ben-Baruch A. Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Seminars Cancer Biol 2006, 16:38-52.
28. -/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scan J Immunol 2010, 72:540-547.
29. Bogdanova A., Mihov D., Lutz H., Saam B., Gassmann M., Vobel J. Enhanced erythrophagocytosis in polycytemic mice overexpressing erythropoietin. Blood 2007, 110:762-769.
30. Ribatti D., Crivellato E., Nico B., Guidolin D., Gassmann M., Djonov V. Mast cells and macrophages in duodenal mucosa of mice overexpressing erythropoietin. J Anat 2009, 215:548-554.
31. Harron Z.A., Amin K., Jinag X., Arcasoy M.O. A novel role for erythropoietin during fibrin-induced wound healing response. Am J Pathol 2003, 163:993-1000.
32. Lifshitz L., Tabak G., Gassmann M., Mittelman M., Neumann D. Macrophages as novel target cell for erythropoietin. Haematologica 2010, 95:1823-1831.
33. De Luisi A., Binetti L., Ria R., Ruggieri S., Berardi S., Catacchio I., et al. Erythropoietin is involved in the angiogenic potential of bone marrow macrophages in multiple myeloma. Angiogenesis 2013, 16:963-973.
34. Moschetta M., Di Pietro G., Ria R., Gnoni A., Mangialardi G., Guarini A., et al. Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma. Eur J Cancer 2010, 46:420-429.
35. Mitsiades C.S., Rouleau C., Echart C., Menon K., Teicher B., Di Staso M., et al. Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias. Clin Cancer Res 2009, 15:1210-1221.
36. Palumbo A., Larocca A., Genuardi M., Kotwika K., Gay F., Rossi D., et al. Melphalan, prednisone, thalidomide, and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. Haematologica 2010, 95:1144-1149.